Half Year Result 20171
CSL Delivers Exceptional Performance
Melbourne, Australia — 15/02/2017
Global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP). Reported earnings per share (EPS) grew 14%. Underlying2 NPAT grew 36% and earnings per share (EPS) increased 39% on a constant currency (CC)3 basis, after excluding the one-off items related to the Novartis influenza vaccines business acquisition during the previous period.
- Revenue $3,677 million
- Earnings before interest and tax (EBIT) $1,095 million
- Underlying EBIT up 38% at CC
- NPAT $806 million
- Underlying NPAT up 36% at CC
- EPS $1.77
- Reported EPS up 14%
- Underlying EPS up 39% at CC
- Interim dividend4 increased to $0.64 per share
1 All figures are expressed in US dollars unless otherwise stated. 2 Underlying excludes from 1H16 financials the one off items relating to the Novartis influenza vaccines business (NVS-IV), which was acquired on 31 July 2015. 3 Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note for further detail. 4 For shareholders with an Australian registered address, dividends will be unfranked for Australian tax purposes and paid on 13 April 2017 in A$ at an amount of A$0.837760 per share (at an exchange rate of A$1.3090/US$1.00). For shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.892160 per share (at an exchange rate of NZ$1.3940/US$1.00). The exchange rates used are fixed at the date of dividend determination. All other shareholders will be paid in US$. CSL also offers shareholders the opportunity to receive dividend payments in US$ by direct credit to a US bank account.
Download This Release
CSL Half Year results announcement for 2017
Details about CSL's results are included in the company's 4D statement, investor presentation slides and webcast.
For further information, please contact:
Head of Investor Relations
Phone: +613 9389 3407
Head of Asia Pacific Communications
Phone: +613 9389 3473
Mobile: +61 412 635 483